Minimal Change Disease

• Podocyte foot process effacement: The primary pathologic lesion involves diffuse effacement (flattening) of podocyte foot processes visualized only on electron microscopy. This effacement disrupts the slit diaphragm architecture, which normally consists of adhesion molecules (nephrin, podocin, and CD2-associated protein) that maintain the barrier function. The mechanism appears to involve T cell-derived circulating permeability factors (possibly lymphokines such as vascular permeability factor or angiopoietin dysregulation) that directly damage podocytes, causing loss of their normal architecture. This is supported by the observation that disease frequently recurs after kidney transplantation if the native kidney is retained, suggesting a circulating humoral factor. Additionally, podocyte dysfunction impairs their contractile properties mediated by actin-myosin interactions, further compromising barrier integrity.

• Selective proteinuria mechanism: The proteinuria in MCD is characteristically selective, meaning primarily small molecular weight proteins (especially albumin, 66 kDa) are lost while larger proteins like immunoglobulins are retained. This selectivity contrasts with non-selective proteinuria seen in other glomerulonephritides. The mechanism reflects loss of charge selectivity rather than complete size selectivity barrier loss. Normal glomeruli possess a negatively charged glycocalyx (composed of heparan sulfate and other glycosaminoglycans) that repels negatively charged proteins like albumin. In MCD, the charge barrier is compromised while the size barrier remains relatively intact, allowing preferential passage of albumin. The loss of charge selectivity explains why proteinuria often exceeds 3.5 g/day despite minimal structural changes. This selective proteinuria is crucial diagnostically because it suggests MCD over membranoproliferative or membranous disease.

• Immune dysregulation and T cell abnormalities: MCD is increasingly recognized as an immune-mediated disorder involving T cell dysfunction. Multiple lines of evidence support this: (1) strong association with atopy and allergic conditions; (2) frequent occurrence after infections or vaccinations; (3) rapid response to corticosteroids and immunosuppression; (4) frequent relapse patterns suggesting ongoing immune dysregulation. Molecular studies demonstrate abnormal T cell cytokine production, with increased production of interleukin-13 (IL-13) and vascular permeability factor (VPF) by T cells in some patients. IL-13 can directly increase glomerular permeability and activate podocytes. Additionally, regulatory T cell (Treg) dysfunction has been documented in MCD patients, contributing to loss of immune tolerance. The association with Hodgkin lymphoma and other malignancies in adult-onset MCD suggests that abnormal immune surveillance may be relevant in older patients. This immune basis explains the remarkable steroid responsiveness and the high frequency of relapses when immunosuppression is withdrawn.

• Podocyte cytoskeletal dysfunction: Beyond foot process effacement, MCD involves abnormalities in the podocyte cytoskeleton, particularly disruption of the actin-filament network. Podocytes contain abundant F-actin that maintains foot process structure and contributes to the contractile properties that help regulate filtration. In MCD, there is abnormal actin polymerization and altered expression of actin-associated proteins. This cytoskeletal dysfunction may be mediated by the circulating permeability factors mentioned above. Additionally, alterations in small GTPase signaling (including Rho/Rac pathways) have been implicated in disrupting the normal cytoskeletal dynamics necessary for foot process maintenance. The reversibility of these changes with corticosteroid therapy (foot processes re-extend in responders) supports that the changes are functional rather than permanent structural damage.

• Complement and minimal immune complex deposition: Unlike many other glomerulonephritides, MCD classically shows absent or minimal immunoglobulin and complement deposition on immunofluorescence microscopy. However, recent data suggests subtle complement activation may occur at the podocyte level. The absence of immune complexes distinguishes MCD from post-infectious glomerulonephritis and lupus nephritis. The mechanism of glomerular injury in MCD therefore differs fundamentally from immune-complex mediated diseases, further supporting the "podocyte toxin" hypothesis involving circulating factors rather than in situ immune complex formation.

• Albumin metabolism and renal handling: The massive proteinuria in MCD leads to substantial albumin losses (often 3.5-15 g/day). This drives compensatory hepatic synthesis of albumin and other proteins (including clotting factors and lipoproteins), which contributes to the characteristic laboratory findings of hypoalbuminemia and hyperlipidemia. The loss of specific proteins like transferrin and ceruloplasmin may contribute to anemia and other metabolic consequences. The kidney's ability to reabsorb filtered proteins via megalin-cubilin receptor-mediated endocytosis becomes saturated at high filtered protein loads, explaining the massive proteinuria despite normal GFR.

• Primary/idiopathic minimal change disease: Accounts for >90% of MCD cases. This is the most common form in both children and adults. The pathogenesis involves genetic predisposition combined with environmental triggers. Genome-wide association studies have identified susceptibility loci, though specific genetic mutations responsible for MCD remain largely unknown. The strong association with HLA-DQ8 and HLA-DR7 in some populations suggests immunogenetic components. No specific environmental trigger is identified in most cases, though some patients report onset after infections (particularly respiratory infections), vaccinations (especially live vaccines), or allergen exposure. The idiopathic form is characterized by excellent steroid responsiveness.

• Association with atopy and allergic conditions: Patients with MCD have increased incidence of atopic diseases including asthma, eczema, and allergic rhinitis. Some series report 30-50% of MCD patients have personal or family history of atopy. This association supports the immune dysregulation hypothesis. In children, onset of MCD sometimes clusters around seasonal allergen exposure or follows infectious triggers that may provoke allergic responses. The mechanism likely involves Th2-mediated immune responses with abnormal IL-4 and IL-13 production. This atopic association is important clinically because it suggests counseling regarding allergen avoidance may be beneficial and highlights the immunologic nature of the disease.

• Infection-associated and vaccine-triggered MCD: Numerous infectious pathogens have been temporally associated with MCD onset, including respiratory infections (particularly varicella-zoster, measles), gastrointestinal infections, and tuberculosis. Vaccinations (especially live-attenuated vaccines) occasionally precede disease onset. The mechanism likely involves molecular mimicry or bystander immune activation triggering T cell responses that secondarily damage podocytes. These cases are particularly important clinically because they may warrant investigation for underlying infection and may respond differently to immunosuppression depending on the underlying pathogen.

• Malignancy-associated MCD in adults: Hodgkin lymphoma is the malignancy most commonly associated with MCD, occurring in 1-5% of adult MCD cases and in 5-10% of MCD cases in older adults. Other malignancies occasionally reported include non-Hodgkin lymphoma, solid tumors, and sarcomas. The mechanism may involve lymphoma-derived cytokines or immune dysregulation secondary to malignancy. This association mandates malignancy screening in all adults with newly diagnosed MCD, particularly those over age 40. Resolution of MCD after successful cancer treatment supports the causal relationship in some cases.

• Drug-associated MCD: Several medications have been linked to MCD including NSAIDs (particularly in older patients), lithium, and pamidronate. NSAIDs may trigger MCD through immune mechanisms or by direct podocyte toxicity. The incidence of NSAID-associated MCD is low but important to recognize. Lymphomas treated with certain chemotherapy agents may develop MCD. These secondary forms may have different natural histories and treatment responses compared to idiopathic MCD.

• Association with systemic diseases: MCD can rarely occur in association with systemic lupus erythematosus (though full lupus nephritis is more common), Sjögren syndrome, celiac disease, and inflammatory bowel disease. These associations suggest potential crossover between MCD and other immune-mediated glomerulonephritides. The mechanism may involve shared immunologic pathways or molecular mimicry.

• Genetic and familial factors: While most MCD is sporadic, rare familial cases have been reported, suggesting genetic predisposition in some families. Most familial cases are inherited in an autosomal recessive pattern. Genes involved in podocyte structure (such as NPHS1 encoding nephrin, NPHS2 encoding podocin) can cause steroid-resistant nephrotic syndrome with MCD-like appearance, highlighting the genetic heterogeneity. These genetic forms typically present in infancy and are steroid-resistant, distinguishing them from idiopathic MCD.

• Nephrotic syndrome complex: MCD classically presents with the tetrad of nephrotic syndrome: massive proteinuria (>3.5 g/day, often 3.5-15 g/day), hypoalbuminemia (typically <2.5 g/dL), edema, and hyperlipidemia. The pathophysiology of nephrotic syndrome reflects the massive urinary protein loss exceeding hepatic synthesis capacity, resulting in intravascular volume depletion despite clinical edema, activation of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system leading to sodium retention, and redistribution of intravascular fluid to interstitial space. The nephrotic syndrome develops acutely in children (often over days to weeks) but may have more insidious onset in adults.

• Edema as presenting symptom: Edema is the most common presenting symptom, particularly in children. Edema in MCD is characteristically pitting, generalized, and initially periorbital and lower extremity in distribution. Morning periorbital edema is often the first symptom noticed by parents in children. The edema results from hypoalbuminemia (decreased colloid osmotic pressure) combined with increased renal sodium reabsorption secondary to perceived intravascular volume depletion. Unlike in primary renal disease from other causes, the edema in MCD responds dramatically to corticosteroids, often resolving within 1-2 weeks of treatment initiation. The degree of edema correlates roughly with the severity of hypoalbuminemia but not necessarily with proteinuria magnitude.

• Foamy urine: Many patients report foamy or frothy urine, reflecting the massive proteinuria. The presence of foamy urine should prompt urinalysis and quantification of proteinuria. While foamy urine is not specific (occurring in any significant proteinuria), it is clinically important because it alerts patients to seek care and helps confirm the presence of proteinuria.

• Fatigue and weakness: Patients frequently experience fatigue, malaise, and generalized weakness. This results from multiple factors: hypoalbuminemia and malnutrition from protein losses, anemia (from transferrin losses in urine), hyperlipidemia, and the systemic effects of nephrotic syndrome. Some fatigue may relate to activation of inflammatory pathways. These symptoms often improve as nephrotic syndrome resolves with treatment.

• Respiratory symptoms in severe cases: Severe nephrotic syndrome with massive edema can cause pulmonary edema, presenting with dyspnea, orthopnea, and sometimes acute respiratory distress. This is particularly concerning in children with acute-onset MCD. Pulmonary edema may occur acutely in the setting of infection or intravascular volume overload. Some patients develop pleural effusions. These complications require prompt corticosteroid therapy and supportive care.

• Abdominal symptoms: Abdominal pain, abdominal distension, and diarrhea may occur in MCD. These symptoms likely result from mesenteric edema and electrolyte abnormalities. Diarrhea may also reflect protein malabsorption from intestinal wall edema. These symptoms typically resolve with treatment of the nephrotic syndrome.

• Absence of systemic symptoms: Unlike in secondary causes of nephrotic syndrome, MCD patients typically lack systemic manifestations such as fever, arthralgias, rash, or constitutional symptoms. The presence of systemic symptoms should prompt investigation for alternative diagnoses such as lupus nephritis, vasculitis, or post-infectious glomerulonephritis. This absence of systemic disease is an important clinical clue suggesting primary glomerulonephritis.

• Preserved renal function at presentation: A hallmark of MCD is normal or near-normal GFR at presentation, contrasting with many other glomerulonephritides. Serum creatinine is typically normal or only mildly elevated. Blood pressure is usually normal or mildly elevated. This preserved renal function is crucial diagnostically and prognostically, as it suggests a functional rather than structural glomerular process.

• Variable age of presentation: In children, MCD presents typically between ages 2-6 years, with peak incidence around age 3-4 years. In adults, MCD can present at any age but increases in frequency after age 40. Adult-onset MCD may have different clinical features including higher frequency of hematuria and more frequent relapses. The typical presentation in children is an otherwise healthy child who develops sudden-onset nephrotic syndrome, whereas adult presentation may be more insidious.

• Minimal or absent hematuria: MCD classically presents with absent hematuria or only microscopic hematuria (if present, <10 RBCs/hpf). The presence of gross hematuria or significant microscopic hematuria (>40 RBCs/hpf) should raise suspicion for alternative diagnoses such as IgA nephropathy, post-infectious glomerulonephritis, or lupus nephritis. This absence of hematuria is diagnostically useful in distinguishing MCD from other common causes of nephrotic syndrome. However, some authors report mild hematuria in up to 10% of MCD cases, particularly in adults.

• Normal serum complement levels: Unlike post-infectious glomerulonephritis, MCD patients have normal serum C3 and C4 levels. Low complement levels should prompt investigation for lupus, membranoproliferative glomerulonephritis, or post-infectious disease. This is a useful distinguishing feature.

• Clinical variants - Relapsing vs steroid-resistant disease: Some patients have a single episode of MCD (complete remission with steroid therapy), while others experience frequent relapses (20-40% of children, higher in adults). Steroid-responsive MCD refers to complete remission within 4 weeks of corticosteroid initiation; steroid-dependent disease refers to relapses occurring during or within 2 weeks of stopping steroids; steroid-resistant MCD refers to failure to achieve complete remission after 4 weeks of corticosteroid therapy. These clinical variants have important prognostic and therapeutic implications. Steroid-resistant disease may actually represent focal segmental glomerulosclerosis (FSGS) or other entities misdiagnosed as MCD.

• Clinical presentation as first diagnostic clue: The classic presentation of nephrotic syndrome (proteinuria >3.5 g/day, hypoalbuminemia, edema, hyperlipidemia) with preserved renal function, normal complement levels, and absent hematuria strongly suggests MCD. In children age 2-10 with pure nephrotic syndrome (no hematuria, normal renal function, normal BP), presumptive diagnosis of MCD is sufficiently reliable that kidney biopsy is often deferred in favor of empiric corticosteroid trial. In adults and atypical presentations, biopsy is more frequently obtained. The clinical presentation filters the differential diagnosis substantially.

• Urinalysis findings: Urinalysis in MCD demonstrates heavy proteinuria with absence or minimal hematuria. The urine sediment is characteristically clean or shows only a few RBCs

Initial supportive care

• Sodium and fluid restriction: first-line for edema, since sodium retention (not water excess alone) drives the anasarca. Dietary sodium restriction precedes diuretics.
• Loop diuretics (e.g., furosemide): used for symptomatic edema, but cautiously — many patients are intravascularly underfilled, and brisk diuresis precipitates prerenal AKI and thrombosis. For refractory anasarca or effusions, IV albumin followed by a loop diuretic is a recognized strategy.
• Infection prevention: pneumococcal and annual influenza vaccination per CDC/ACIP; live vaccines are deferred while on high-dose immunosuppression.

First-line definitive therapy

• Oral corticosteroids (prednisone/prednisolone): the KDIGO 2021 Glomerular Diseases guideline recommends daily prednisolone as initial therapy for MCD in both children and adults. Children: 60 mg/m²/day (or 2 mg/kg/day, capped) daily for 4–6 weeks, then alternate-day dosing with taper over a total of 8–12 weeks. Adults: 1 mg/kg/day (or alternate-day equivalent), continued to remission and then tapered; adults remit more slowly, so up to 16 weeks may be needed before declaring steroid resistance. Steroids are thought to act both on lymphocyte cytokine production and directly on the podocyte cytoskeleton, though the precise mechanism is not established.
• In children with typical presentation, KDIGO endorses treating empirically without biopsy.

Relapse and escalation

• Repeat steroid course for infrequent relapses.
• Steroid-sparing agents for frequently relapsing or steroid-dependent disease (KDIGO 2021): cyclophosphamide, calcineurin inhibitors (cyclosporine, tacrolimus), mycophenolate mofetil, or rituximab (anti-CD20). Rituximab is increasingly favored in children with steroid-dependent disease for its steroid- and CNI-sparing effect.
• Steroid resistance: in children, KDIGO 2021 defines this as failure to achieve complete remission after 4 weeks of daily prednisolone at standard dose (some centers extend the trial to 6–8 weeks before applying the label); in adults the interval is longer, as above. Steroid resistance mandates kidney biopsy if not already performed, plus consideration of genetic testing in young children — the lesion is often FSGS or a podocyte gene mutation, not true MCD.

Adjunctive and contraindicated

• RAAS blockade (ACE inhibitor or ARB) and statins are reserved for persistent proteinuria/nephrotic-range disease that does not remit; they are not routine in steroid-responsive childhood MCD. ACE inhibitors are contraindicated in pregnancy.
• Routine prophylactic anticoagulation is not recommended in MCD, unlike membranous nephropathy.
• Avoid NSAIDs (an MCD trigger and a nephrotoxin) and avoid abrupt steroid withdrawal.

Complications of the nephrotic state

• Infection — EMERGENCY: urinary loss of IgG and alternative-pathway components (factor B, properdin) plus edema fluid as culture medium predisposes to spontaneous bacterial peritonitis and sepsis, classically Streptococcus pneumoniae and other encapsulated organisms. Signaled by fever, abdominal pain and tenderness in an edematous child; diagnostic paracentesis and empiric antibiotics must not be delayed.
• Venous thromboembolism — EMERGENCY: urinary loss of antithrombin III with compensatory hepatic synthesis of fibrinogen and clotting factors creates a hypercoagulable state. Signaled by flank pain with gross hematuria and worsening proteinuria (renal vein thrombosis), unilateral leg swelling, or acute dyspnea/pleuritic pain (pulmonary embolism). Risk in MCD is real but lower than in membranous nephropathy.
• Acute kidney injury: from intravascular volume depletion, aggressive diuresis, NSAIDs, or ischemic ATN; most common in older adults with MCD. Signaled by rising creatinine with bland sediment.
• Hyperlipidemia and accelerated atherosclerosis: hypoalbuminemia stimulates hepatic lipoprotein synthesis and reduces LDL clearance.
• Metabolic protein losses: transferrin loss (microcytic anemia resistant to iron), vitamin D–binding protein loss (hypocalcemia, secondary hyperparathyroidism), thyroxine-binding globulin loss (low total T4 with normal TSH — a classic distractor), and protein malnutrition with growth impairment.

Complications of therapy

• Corticosteroids: growth suppression, cushingoid habitus, hyperglycemia, hypertension, cataracts/glaucoma, osteoporosis and avascular necrosis, behavioral change. Adrenal crisis after abrupt withdrawal is an emergency — signaled by hypotension, hyponatremia, hypoglycemia.
• Cyclophosphamide: gonadal toxicity/infertility, marrow suppression, and hemorrhagic cystitis from acrolein (prevented with hydration and mesna); later bladder malignancy.
• Calcineurin inhibitors: dose-dependent nephrotoxicity with chronic interstitial fibrosis, hypertension, hyperkalemia; gingival hyperplasia and hirsutism with cyclosporine, new-onset diabetes with tacrolimus.
• Rituximab: infusion reactions, hypogammaglobulinemia with late infection, hepatitis B reactivation (screen before use), and rarely PML.

• The histologic triad: normal glomeruli on light microscopy, negative immunofluorescence, and diffuse podocyte foot process effacement on electron microscopy. This triad defines MCD, but an identical picture occurs in FSGS when sclerotic (deep juxtamedullary) glomeruli are missed on sampling and in inherited podocytopathies (*NPHS1*/nephrin, *NPHS2*/podocin) — the clinical course, above all steroid responsiveness, resolves the ambiguity.
• Best next step in a 2–6 year old with periorbital edema, heavy selective proteinuria, normal creatinine, no hematuria, normal complements: start empiric corticosteroids, not biopsy. KDIGO 2021 supports treating typical childhood nephrotic syndrome without histology; biopsy is reserved for atypical features (gross hematuria, hypocomplementemia, renal insufficiency, age <1 or >12 years) or steroid resistance.
• Urine sediment buzzwords: oval fat bodies and fatty casts, showing a Maltese cross under polarized light, in an otherwise bland sediment — no RBC casts, no dysmorphic red cells. RBC casts point to a nephritic process instead.
• Selective proteinuria (albumin lost, immunoglobulins retained) is the MCD signature and reflects loss of the charge barrier with a largely preserved size barrier.
• Adults are different: MCD is a minority of adult nephrotic syndrome, biopsy is essentially always required, remission takes longer, and secondary causes must be sought — Hodgkin lymphoma is the classic malignancy association, and NSAIDs are the classic drug trigger (often with concurrent acute interstitial nephritis).
• Do not confuse the two thrombosis stems: renal vein thrombosis is most strongly associated with membranous nephropathy; MCD carries a lower, though real, VTE risk, and routine prophylactic anticoagulation is not recommended.
• Low total T4 with a normal TSH in a nephrotic patient reflects urinary thyroxine-binding globulin loss, not hypothyroidism — a frequent distractor.
• Prognosis: the great majority of children remit with steroids and progression to ESKD is rare; relapse is common but does not itself imply misdiagnosis. Persistent steroid resistance should redirect you to FSGS or a genetic podocytopathy.